EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review

Siyuan Cui, Na Wang, Yangyueying Liang, Yuan Meng, Xinyi Shu, Fanming Kong

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112903 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Siyuan Cui und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Changling Road No.88, Xiqing District, Tianjin…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immune Checkpoint Inhibitors, Clinical Trials as Topic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 122 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The reduction in lung cancer mortality rates over the past decade can be partially ascribed to advancements in immunotherapy. Immune checkpoint inhibitors (ICIs) have transformed the therapeutic landscape for advanced non-small cell lung cancer (NSCLC) and have recently been evaluated in multiple clinical trials to confirm their safety and efficacy in the neoadjuvant, adjuvant and perioperative settings for patients with resectable NSCLC. The Food and Drug Administration (FDA) has granted approval for adjuvant atezolizumab following platinum-doublet chemotherapy, neoadjuvant nivolumab and platinum-doublet chemotherapy, adjuvant pembrolizumab after platinum-doublet chemotherapy, and neoadjuvant/adjuvant pembrolizumab for resectable NSCLC, with potential forthcoming approvals for additional agents or indications. Novel data, approvals, and emerging research findings are dramatically shifting the accepted standards of care over just a few years. Despite these advances, the optimal application of these treatments is not entirely straightforward. This article summarizes the biological rationale for immunotherapy and the important clinical trials regarding perioperative ICIs. We also further outline the controversies and future directions to better guide the individualized treatment of NSCLC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmune Checkpoint InhibitorsClinical Trials as TopicHumansNeoadjuvant TherapyImmunotherapyPerioperative CareAnimals

Stichwörter der Autor:innen

AdjuvantImmune checkpoint inhibitorsImmunotherapyNeoadjuvantPerioperativeResectable non-small cell lung cancer

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Changling Road No.88, Xiqing District, Tianjin 300381, China; Tianjin Cancer Institute of Traditional Chinese Medici…

Zitieren

APA

Cui, S., Wang, N., Liang, Y., Meng, Y., Shu, X., & Kong, F. (2024). Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112903

Vancouver

Cui S, Wang N, Liang Y, Meng Y, Shu X, Kong F. Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112903

BibTeX
@article{Cui2024,
  author = {Cui, Siyuan and Wang, Na and Liang, Yangyueying and Meng, Yuan and Shu, Xinyi and Kong, Fanming},
  title = {Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112903}
}
Kostenlos starten →